000285043 001__ 285043
000285043 005__ 20260209102601.0
000285043 0247_ $$2doi$$a10.1002/mds.70070
000285043 0247_ $$2pmid$$apmid:41048081
000285043 0247_ $$2pmc$$apmc:PMC12882055
000285043 0247_ $$2ISSN$$a0885-3185
000285043 0247_ $$2ISSN$$a1531-8257
000285043 037__ $$aDZNE-2026-00167
000285043 041__ $$aEnglish
000285043 082__ $$a610
000285043 1001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b0$$eFirst author
000285043 245__ $$aA Biomarker-Based Classification of Corticobasal Syndrome.
000285043 260__ $$aNew York, NY$$bWiley$$c2026
000285043 3367_ $$2DRIVER$$aarticle
000285043 3367_ $$2DataCite$$aOutput Types/Journal article
000285043 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770628901_24270
000285043 3367_ $$2BibTeX$$aARTICLE
000285043 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285043 3367_ $$00$$2EndNote$$aJournal Article
000285043 520__ $$aCorticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau-predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD). Lewy-type α-synucleinopathies (LTS), TDP-43 proteinopathies, and mixed pathologies may also underlie CBS. The clinical impact of these pathologies remains poorly understood.To subclassify CBS patients in vivo using biomarkers for amyloid-β (Aβ), Tau, and α-synuclein (αSyn), and assess the clinical relevance of this stratification.We conducted a prospective cohort study of 50 CBS patients at LMU University Hospital Munich. Biomarker analysis included cerebrospinal fluid (CSF) Aβ42 and Aβ42/40, [18F]flutemetamol Aβ-PET, [18F]PI-2620 tau-PET, and αSyn seed amplification assays in CSF. CSF neurofilament light chain (NfL) served as a marker of neurodegeneration. Patients were stratified into six groups based on biomarker positivity.Tau positivity was found in 90% of CBS cases, Aβ in 28%, and αSyn in 24%. Stratification identified: 52% consistent with tau-predominant pathology, 18% with AD, 10% with AD+LTS, 10% with tau-predominant+LTS, 4% with isolated LTS, and 6% unclassified. αSyn positivity was more frequent in AD-CBS (36%) than in tau-predominant-CBS (16%). Aβ-positive cases showed greater cognitive impairment; Tau positivity correlated with worse motor symptoms; αSyn-positive patients had milder motor symptoms, slower progression, and lower NfL levels.CBS is molecularly heterogeneous. Biomarker-based classification may enhance diagnostic precision and support personalized therapeutic strategies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000285043 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285043 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000285043 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285043 650_7 $$2Other$$aproteinopathies
000285043 650_7 $$2Other$$atau‐PET
000285043 650_7 $$2Other$$aα‐synuclein seed amplification assay
000285043 650_7 $$2Other$$aβ‐amyloid
000285043 650_7 $$2NLM Chemicals$$aBiomarkers
000285043 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000285043 650_7 $$2NLM Chemicals$$atau Proteins
000285043 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000285043 650_7 $$2NLM Chemicals$$aPeptide Fragments
000285043 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-42)
000285043 650_2 $$2MeSH$$aHumans
000285043 650_2 $$2MeSH$$aMale
000285043 650_2 $$2MeSH$$aFemale
000285043 650_2 $$2MeSH$$aAged
000285043 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000285043 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000285043 650_2 $$2MeSH$$aMiddle Aged
000285043 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000285043 650_2 $$2MeSH$$aPositron-Emission Tomography
000285043 650_2 $$2MeSH$$aalpha-Synuclein: cerebrospinal fluid
000285043 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000285043 650_2 $$2MeSH$$aProspective Studies
000285043 650_2 $$2MeSH$$aCorticobasal Degeneration: classification
000285043 650_2 $$2MeSH$$aCorticobasal Degeneration: cerebrospinal fluid
000285043 650_2 $$2MeSH$$aCorticobasal Degeneration: diagnostic imaging
000285043 650_2 $$2MeSH$$aPeptide Fragments: cerebrospinal fluid
000285043 650_2 $$2MeSH$$aAged, 80 and over
000285043 7001_ $$0P:(DE-2719)9002620$$aBernhardt, Alexander Maximilian$$b1$$eFirst author
000285043 7001_ $$0P:(DE-2719)9000882$$aWeidinger, Endy$$b2$$udzne
000285043 7001_ $$0P:(DE-2719)9001214$$aFietzek, Urban M$$b3$$udzne
000285043 7001_ $$0P:(DE-2719)9002626$$aJäck, Alexander$$b4$$udzne
000285043 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b5
000285043 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b6$$udzne
000285043 7001_ $$aBauer, Theresa$$b7
000285043 7001_ $$aFranzmeier, Nicolai$$b8
000285043 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b9$$udzne
000285043 7001_ $$aTauopathies, German Imaging Initiative for$$b10$$eCollaboration Author
000285043 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b11$$eLast author
000285043 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b12$$eLast author$$udzne
000285043 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b13$$eLast author$$udzne
000285043 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.70070$$gVol. 41, no. 1, p. 129 - 142$$n1$$p129 - 142$$tMovement disorders$$v41$$x0885-3185$$y2026
000285043 8564_ $$uhttps://pub.dzne.de/record/285043/files/DZNE-2026-00167.pdf$$yRestricted
000285043 8564_ $$uhttps://pub.dzne.de/record/285043/files/DZNE-2026-00167.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002620$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000882$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001214$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002626$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285043 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b6$$kExtern
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000285043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000285043 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285043 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000285043 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-10$$wger
000285043 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-10$$wger
000285043 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-10
000285043 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2025-11-10
000285043 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000285043 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x1
000285043 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x2
000285043 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x3
000285043 980__ $$ajournal
000285043 980__ $$aEDITORS
000285043 980__ $$aVDBINPRINT
000285043 980__ $$aI:(DE-2719)1111015
000285043 980__ $$aI:(DE-2719)1111016
000285043 980__ $$aI:(DE-2719)1110007
000285043 980__ $$aI:(DE-2719)5000022
000285043 980__ $$aUNRESTRICTED